Our findings are supported by earlier in vitro work showing that the noncompetitive anti-HER2 monoclonal antibody combination pertuzumab plus trastuzumab reduced the amount of membranous HER2 on breast cancer cells, but maintained ADCC activity [14, 15]. Here, ERBB2 is linked to breast cancer.